PIM1 anticorps (AA 25-86)

N° du produit ABIN7169141

Détail du produit anti-PIM1 anticorps

Antigène: PIM1 (Pim-1 Oncogene (PIM1))

Épitope: AA 25-86

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PIM1 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Serine/threonine-protein kinase pim-1 protein (25-86AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur PIM1

Antigène: PIM1 (Pim-1 Oncogene (PIM1))

Autre désignation: PIM1 (PIM1 Produits)

Synonymes: anticorps PIM, anticorps Pim-1, anticorps PIM1, anticorps pim, anticorps pim-1, anticorps pim3, anticorps Pim-1 proto-oncogene, serine/threonine kinase, anticorps proviral integration site 1, anticorps Pim-1 proto-oncogene, serine/threonine kinase L homeolog, anticorps PIM1, anticorps Pim1, anticorps pim1, anticorps pim1.L

Sujet:

Background: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.

Aliases: Oncogene PIM 1 antibody, Oncogene PIM1 antibody, PIM 1 antibody, pim 1 kinase 44 kDa isoform antibody, Pim 1 kinase antibody, pim 1 oncogene (proviral integration site 1) antibody, Pim 1 oncogene antibody, PIM antibody, PIM1 antibody, pim1 kinase 44 kDa isoform antibody, PIM1_HUMAN antibody, Pim2 antibody, PIM3 antibody, Proto oncogene serine/threonine protein kinase Pim 1 antibody, Proto-oncogene serine/threonine-protein kinase Pim-1 antibody, Proviral integration site 1 antibody, Proviral integration site 2 antibody

UniProt: P11309

Pathways: Glycosaminoglycan Metabolic Process